Drugs / Flunarizine
Flunarizine
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00752466 | Mar 2003 → Mar 2004 | migraine disorder | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06153186 | Sep 2019 → May 2023 | childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy | University of British Columbia | Terminated | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT06499116 | Oct 2024 → Dec 2026 expected | migraine disorder | Jordi Gol Institute for Primary Care Research | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04702971 | Feb 2021 → Dec 2024 | migraine disorder | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT04064814 | Sep 2019 → Apr 2021 | migraine disorder | All India Institute of Medical Sciences, Bhubaneswar | Completed | No outcome recorded |
| Phase 4 | NCT02747940 | Dec 2015 → Dec 2019 | fibromyalgia, migraine disorder | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT02639598 | Jun 2012 → Dec 2014 | migraine disorder | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT00740259 | Sep 2004 → May 2007 | schizophrenia | Ambulatório de Bipolaridade | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07354126 | Sep 2025 → Feb 2026 overdue | migraine disorder | Muhammad Aamir Latif | Recruiting | No outcome recorded |
| — | NCT06796725 | Feb 2025 → Jun 2026 overdue | migraine disorder | Ruijin Hospital | Recruiting | No outcome recorded |
| — | NCT06162819 | Jan → Jun 2024 | migraine disorder | Shalamar Institute of Health Sciences | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07445464 Comparator | Apr → Jun 2026 overdue | — | Aspartes Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07068815 Comparator | Sep 2025 → Mar 2027 expected | migraine without aura | Guangzhou University of Chinese Medicine | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07655700 Comparator | Jul 2026 → Mar 2027 expected | — | Chittagong Medical College | Not yet recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT03712917 Comparator | Mar 2019 | migraine disorder | Ataturk University | Completed | No outcome recorded |
| — | NCT03461874 Background | Mar 2018 → Jul 2020 | migraine without aura | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Completed | No outcome recorded |
| — | NCT02580968 Comparator | Mar 2015 → Dec 2017 | migraine disorder | Shanghai University of Traditional Chinese Medicine | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flunarizine | “Pharmacological prophylaxis will be prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or...” NCT03461874 ↗ |
| Known as | Flunarizina | ChEMBL registry synonym — accepted as the source's own label CHEMBL30008 ↗ |
| Known as | Flunarizine (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL30008 ↗ |
| Known as | Flunarizine dihydroch | ChEMBL registry synonym — accepted as the source's own label CHEMBL30008 ↗ |
| Known as | FLUNARIZINE DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL30008 ↗ |
| Known as | Flunarizine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL30008 ↗ |
| Known as | flunarizine hydrochloride | “Flunarizine (flunarizine hydrochloride) is indicated for prophylaxis of migraine (with and without aura) in patients with frequent and severe attacks, who have not responded to...” NCT06153186 ↗ |
| Known as | Flurizin | ChEMBL registry synonym — accepted as the source's own label CHEMBL30008 ↗ |
| Known as | Migarid-10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL30008 ↗ |
| Known as | NSC-757807 | ChEMBL registry synonym — accepted as the source's own label CHEMBL30008 ↗ |
| Known as | R 14,950 | ChEMBL registry synonym — accepted as the source's own label CHEMBL30008 ↗ |
| Known as | Sibelium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06796725 ↗ |
| Action | Inhibit | “Flunarizine also has dopamine D2 receptor blocking properties” PMID 19192440 ↗ Sep 2008 |
| Modality | Small molecule | — CHEMBL30008 ↗ |
| Route | Oral | “as an oral drug with long half-life (2-7 weeks)” PMID 19192440 ↗ Sep 2008 |